Abstract
Although dermatomyositis (DM) patients have been included in studies evaluating COVID-19 risk and severity in large cohorts of patients with chronic immune-mediated diseases, there is little data specifically evaluating these in DM patient cohorts. We performed a single-center, retrospective cohort study to evaluate the severity of COVID-19 in DM patients compared to patients with other dermatologic-immune-mediated diseases (DIMDs), and to assess for risk factors related to severe COVID-19 disease courses.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
